OnAsset Intelligence
Global Real Time Tracking and Monitoring Solutions for Clinical trials
US-based clinical-stage oncology company G1 Therapeutics has collaborated with Genentech to conduct a Phase II clinical trial of tecentriq and trilaciclib to treat patients with small-cell lung cancer (SCLC) receiving chemotherapy.
US-based clinical-stage oncology company G1 Therapeutics has collaborated with Genentech to conduct a Phase II clinical trial of tecentriq and trilaciclib to treat patients with small-cell lung cancer (SCLC) receiving chemotherapy.
G1’s trilaciclib (G1T28) is a short-acting intravenous CDK4/6 inhibitor that is being developed to sustain hematopoietic stem cells and enhance immune system function during chemotherapy.
Genetech’s tecentriq is an anti-PD-L1 monoclonal antibody that binds to PD-L1 expressed on tumour cells and tumour-infiltrating immune cells, thereby inhibiting its interactions with both PD-1 and B7.1 receptors.
G1 Therapeutics CEO Mark Velleca said: “We are excited that this combination regimen of trilaciclib plus Tecentriq may benefit patients with small-cell lung cancer, a disease with tremendous unmet medical need.
“Trilaciclib has demonstrated its ability to preserve the immune system from damage by chemotherapy and to enhance T-cell activation, which may augment anti-tumour immunity and be a powerful complement to Tecentriq.”
Expected to commence next year, the drug combination will be applied as a first-line treatment for small-cell lung cancer patients.
Trilaciclib has demonstrated its anti-tumour activity, including a complete response and multiple partial responses, while applied in combination with chemotherapy to patients with SCLC during two ongoing Phase Ib/IIa trials.
The treatment was favourably tolerated, with no occurrence of febrile neutropenia.
Global Real Time Tracking and Monitoring Solutions for Clinical trials
Drug Delivery Development for Advanced Oral Formulations
ZUMEDU Secure Peer-to-Peer Video Conference Solutions for Clinical Researchers